Atum issued patents for genome engineering

By The Science Advisory Board staff writers

August 11, 2021 -- The U.S. Patent and Trademark Office has issued three patents to bioengineering solutions provider Atum. The newly issued patents cover three novel transposase/transposon pairs, adding to Atum's existing two patents within the company's Leap-In Transposase toolbox.

The three patents -- 11,060,098, 11,060,109, and 11,060,086 -- are for three additional orthogonal enzymes and expand the scope of the company's Leap-In Transposase platform. The pairs were engineered using Atum's ProteinGPS platform, which enables the rapid generation of stable transposon integrations and the controlled excision of genetic elements.

With the addition of the new genome engineering technology, the company believes it can apply its bioengineering tools to a spectrum of complex, multidimensional bioengineering applications on the genome level.

Atum's transposon- and transposase-based platform addresses some of the limitations of CRISPR-Cas9 editing technology and has direct applications for efficient recombinant protein expression, cell line development, cell and gene therapy, and other genomic engineering applications, according to the company.

Atum licenses cell line development tools to Rentschler Biopharma
Rentschler Biopharma has signed a full contract development and manufacturing organization license agreement for Atum's Leap-In Transposase platform.
Atum, Phylex accelerate universal SARS coronavirus vaccine
Atum and Phylex BioSciences will collaborate to advance research toward creating a universal vaccine effective against pathogenic coronaviruses, including...
Atum gives labs free access to protein production platform
Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and...

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter